Guideline-directed medical therapy for HF included beta-blockers in combination with either an angiotensin receptor–neprilysin inhibitor, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor blocker in all patients. This evidence concerns the gene MME and hydrops fetalis.